TW202210523A - 用於調節骨髓樣細胞發炎表型之抗ｖｓｉｇ４組合物及方法以及其用途 - Google Patents

用於調節骨髓樣細胞發炎表型之抗ｖｓｉｇ４組合物及方法以及其用途 Download PDF

Info

Publication number
TW202210523A
TW202210523A TW110119507A TW110119507A TW202210523A TW 202210523 A TW202210523 A TW 202210523A TW 110119507 A TW110119507 A TW 110119507A TW 110119507 A TW110119507 A TW 110119507A TW 202210523 A TW202210523 A TW 202210523A
Authority
TW
Taiwan
Prior art keywords
cells
macrophages
agent
myeloid cells
antigen
Prior art date
Application number
TW110119507A
Other languages
English (en)
Chinese (zh)
Inventor
泰蒂安娜 Ｉ 諾維布蘭瑟娃
易格 費爾德曼
史帝芬 Ｌ 薩金斯基
伊莉莎白 酷利巴
豐安 阮
瑪加 拉茲洛格
Original Assignee
美商維西歐製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維西歐製藥公司 filed Critical 美商維西歐製藥公司
Publication of TW202210523A publication Critical patent/TW202210523A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110119507A 2020-05-29 2021-05-28 用於調節骨髓樣細胞發炎表型之抗ｖｓｉｇ４組合物及方法以及其用途 TW202210523A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032337P 2020-05-29 2020-05-29
US63/032,337 2020-05-29

Publications (1)

Publication Number Publication Date
TW202210523A true TW202210523A (zh) 2022-03-16

Family

ID=78722851

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110119507A TW202210523A (zh) 2020-05-29 2021-05-28 用於調節骨髓樣細胞發炎表型之抗ｖｓｉｇ４組合物及方法以及其用途

Country Status (11)

Country Link
US (1) US20230348603A1 (enExample)
EP (1) EP4157886A4 (enExample)
JP (1) JP2023527410A (enExample)
KR (1) KR20230017778A (enExample)
CN (1) CN115996953A (enExample)
AU (1) AU2021281356A1 (enExample)
BR (1) BR112022023892A2 (enExample)
CA (1) CA3182814A1 (enExample)
IL (1) IL298545A (enExample)
TW (1) TW202210523A (enExample)
WO (1) WO2021243169A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133338A2 (en) * 2022-01-10 2023-07-13 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Molecules that bind to neutrophil elastase polypeptides
KR20240058017A (ko) * 2022-10-21 2024-05-03 주식회사 유틸렉스 항-vsig4 항체를 포함하는 항암용 조성물
CN116930505A (zh) * 2023-01-16 2023-10-24 中国人民解放军总医院第五医学中心 血细胞表达的vsig4膜蛋白作为生物标志物在急性单核细胞白血病和急性髓单核细胞白血病诊断中的应用
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
KR20250062590A (ko) * 2023-10-31 2025-05-08 인제대학교 산학협력단 신장 이식 후 만성거부반응 진단용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130204A1 (en) * 2007-04-24 2008-10-30 Eucell Bio Co., Ltd. New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
WO2008151819A2 (en) * 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
EP2376120A2 (en) * 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
KR101730868B1 (ko) * 2013-09-13 2017-04-27 인제대학교 산학협력단 Ｖｓｉｇ４ 억제제를 유효성분으로 포함하는 난소암 예방 또는 치료용 약학조성물
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
EP3645042A4 (en) * 2017-06-26 2021-03-17 Bio-Techne Corporation HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND THEIR MANUFACTURING AND USE METHODS
AU2019351294B2 (en) * 2018-09-28 2025-07-31 Eutilex Co., Ltd. Anti-human VSIG4 antibodies and uses thereof

Also Published As

Publication number Publication date
EP4157886A1 (en) 2023-04-05
WO2021243169A1 (en) 2021-12-02
US20230348603A1 (en) 2023-11-02
CA3182814A1 (en) 2021-12-02
IL298545A (en) 2023-01-01
KR20230017778A (ko) 2023-02-06
EP4157886A4 (en) 2024-10-16
CN115996953A (zh) 2023-04-21
JP2023527410A (ja) 2023-06-28
BR112022023892A2 (pt) 2022-12-27
AU2021281356A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
EP3645571B1 (en) Her3 antigen-binding molecules
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20260098093A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20220363752A1 (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
HK40126807A (en) Cnx antigen-binding molecules
WO2026064353A1 (en) Diagnostics and therapeutics targeting slc13a3